ISSN: 0976-822X

Available online on www.ijcpr.com

International Journal of Current Pharmaceutical Review and Research 2021; 13(2); 24-27

Original Review Article

# A NEW DRUG- VXc-486 TUBERCULOSIS TREATMENT: A REVIEW

**Ayushi[1],** Mr. Praveen Jaiswal[2], Ms. Shaneza Aman[2], Mr. Ashok Kumar Sharma[3], Mr. Purushottam Prajapati[3], Mr. Mehul Kumar Choudhary[4]

[1]Asst. Professor, Sunderdeep pharmacy College, Ghaziabad, UP
[2]PhD Scholar, Dept. of Pharmacy, Lords University, Alwar
[3]PhD Scholar, Dept. of Pharmacy, B.N. University, Udaipur
[4]Asst. Professor, Arya College of Pharmacy, Kukas, Jaipur

**Received: 14-04-2021 / Revised: 22-05-2021 / Accepted: 26-06-2021**
**Corresponding author: Ms. Ayushi**
**Conflict of interest: Nil**

**Abstract**

Tuberculosis (TB) is a communicable disorder from time to time because of the microorganism mycobacterium tuberculosis (MTB). Antitubercular agent acts as inhibiting the growth of Mycobacterium tuberculosis. Antitubercular agents specifically act with the aid of using inhibit the growth of microorganism with the aid of using cell wall synthesis inhibition. VXc-486 is a powerful antitubercular drug belonging with aminobenzimidazole category. The novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibits a couple of drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis. VXc-486 is crystalline and flakes in yellow colour having stable state. It is crystalline solid at room temperature that display physical feature of the drug. VXc-486 is water insoluble strong antitubercular drug that is the Aminobenzimidazole family drug.

**Keywords:** Antitubercular, Aminobenzimidazole, Gyrase B, VXc-486, Potent, characteristic, temperature, inhibits.



## INTRODUCTION

Tuberculosis may be a disease typically caused by the microorganism known as the mycobacterium tuberculosis (MTB). TB is typically affected the lungs but could have an effect on totally different part of the body. Tuberculosis is one among the highest 10 causes of the death in worldwide. In the 2016, about 10.4 million individuals fall sick with tuberculosis and 1.7 million died from the disease. Over ninety fifth of TB deaths occur in low- and middle-income countries. Seven countries account for sixty fourth of the entire, with India leading the count, followed by Republic of Indonesia, China, Philippines, Pakistan, Nigeria, and South Africa. TB may be a leading killer of HIV-positive people: in 2016, 400th of HIV deaths were because of TB (TB).[3-5]

### Transmission

When people with active respiratory organ having TB and therefore the individual cough, sneeze, speak, sing, or spit, they expel infectious aerosol droplets having size of 0.5 to 5.0 µm in diameter is taken by another person can get infected. All of these droplets might transmit the illness,

since the infectious dose of TB is incredibly tiny.[6-7]

**Pathogenesis**

About ninetieth of these infected with TB have asymptomatic, latent TB infection, which is some time called LTBI, with only a tenth life probability that the latent infection can reach overt, active tuberculosis disease. In those with HIV, the possibility of developing active TB will increase to just about 100 pc a year.[8-9]

**Antitubercular Drugs**

Anti Tubercular agent, inhibit the expansion of mycobacterium tuberculosis. These drugs are to be taken together form.

For the treatment of TB, these drugs are given in multi drug therapy (MDT). Many of Antitubercular agents act by inhibit the expansion of bacteria by cell membrane synthesis inhibition and protein synthesis inhibition, which are essential a part of DNA synthesis. But some Anti-T.B. agents act by inhibition of enzymes that are essential for Mycolic acid synthesis.[10]

**First line drugs: -**

Isoniazid
Streptomycin
Ethambutol
Pyrazinamide
Rifampin

**Second line drugs: -**

Capreomycin
Kanamycin
Ethionamide
Ciprofloxacin
P-amino salicylic acid

VXc-486 is a potent antitubercular drug belonging with aminobenzimidazole category. The novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of mycobacterium tuberculosis (M.TB). VXc-486 inhibits the DNA replication and also blocks DNA replication.[11-12]

**Chemistry**

VXc-486 is have crystalline and flakes in yellow color solid state nature. It is crystalline solid at room temperature that show physical characteristic of the drug. VXc-486 is water insoluble potent anti-tubercular drug which is the Amino benzimidazole family drug.[13]

**VXc-486**

Molecular weight: 424.43 gm/mol

Boiling point: 342°C

Melting point: 82°C

Flash Point: 163°C

Solubility: VXc-486 powder soluble in DMSO and insoluble in water.

Storage: VXc-486 Store at room temperature in well closed container.[14]




**Figure 1: Chemical structure**

**Mechanism of Action**

VXc-486 is the novel potent anti-tuberculosis drug family of antituberculosis class which belong the category of aminobenzimidazole.[15-16]

VXc-486 inhibits the DNA gyrase-B which is the topoisomerase $4^{th}$ and blocks the replication stage of DNA. VXc-486 acts as inhibit the multiple drug resistance of Mycobacterium tuberculosis (M.TB.).[17]

**Medicinal uses: -**

Anti-tubercular Activity-

Vxc-486 is act as anti-tubercular agent. It shows anti-tubercular activity by blocking DNA gyrase-B.

Antibacterial Agent-

Vxc-486 is widely used to inhibit the bacterial growth by inhibiting the DNA and cell wall synthesis.[18-19]

**Side effects**

VXc-486 has some following common side effects.[20-21]

Vomiting

Nausea

Dizziness

Anorexia

**REFERENCES**


1. WHO. October 2015. Archived from the original on 23 August 2012. Retrieved 11 February 2016.
2. Ferri, Fred F. (2010). Ferri's differential diagnosis: a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia, PA: Elsevier/Mosby. p. Chapter T. ISBN 0323076998.
3. Delhi: Allied Chambers India Ltd. 1998. p. 352. Archived from the original on 6 September 2020.
4. Nicas M, Nazaroff WW, Hubbard A (2005). "Toward understanding the risk of secondary airborne infection: emission of respirable pathogens". J Occup Environ Hyg. 2 (3): 143–54.
5. Ahmed N, Hasnain S. "Molecular epidemiology of tuberculosis in India: Moving forward with a systems biology approach". Tuberculosis: 2011;91 (5):4073.
6. "Tuberculosis Fact sheet N°104". World Health Organization. November 2010. Archived from the original on 4 October 2006. Retrieved 26 July 2011.
7. https://www.tbfacts.org/tb-drugs.
8. World Health Organization. The End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2015.
9. Frick, M. 2014 report on tuberculosis research funding trends, 2005–2013. 2nd Edition. New York: Treatment Action Group; 2014.
10. TB Alliance (Press Release). TB Alliance advances next-generation TB drug candidate into clinical testing. 2015 February 18.
11. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
12. Sharma AK, Sharma V, Rathor R, Khandelwal M, Sharma M, VXc-486 potent drug: A new drug approach in tuberculosis treatment, J Transl Res 2018 Volume 2 Issue 1; 8-10.
13. https://www.google.co.in/VXc.drugbank.
14. Furin, Jennifer (Case Western Reserve University, Cleveland, OH). E-mail with: Erica Lessem (Treatment Action Group, New York, NY). 2015 June 9.
15. Médecins Sans Frontières. Ready, set, slow down: new and promising DR-TB drugs are grabbing headlines but not reaching patients. Geneva:Médecins Sans Frontières; 2015.
16. USAID and Johnson & Johnson (Press Release). USAID and Johnson & Johnson to tackle antibiotic-resistant tuberculosis. 2014 December 11.

17. Destito, Marc (Otsuka, Tokyo, Japan). E-mail with: Erica Lessem (Treatment Action Group, New York, NY). 2015 June 4.
18. WHO. October 2015. Archived from the original on 23 August 2012. Retrieved 11 February 2016.
19. Cole E, Cook C (1998). "Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies". Am J Infect Control. 26 (4): 453–64.
20. Nicas M, Nazaroff WW, Hubbard A (2005). "Toward understanding the risk of secondary airborne infection: emission of respirable pathogens". J Occup Environ Hyg. 2 (3): 143–54.
21. Skolnik, Richard (2011). Global health 101 (2nd ed.). Burlington, MA: Jones & Bartlett Learning. p. 253. Archived from the original on 6 September 2019.